Monteferrante G, Brioschi S, Caprioli J, Pianetti G, Bettinaglio P, Bresin E, Remuzzi G, Noris M
Transplant Research Center Chiara Cucchi de Alessandri e Gilberto Crespi, Mario Negri Institute for Pharmacological Research, Villa Camozzi, Via Privata Camozzi 3, 24020 Ranica, Bergamo, Italy.
Mol Immunol. 2007 Mar;44(7):1704-8. doi: 10.1016/j.molimm.2006.08.004. Epub 2006 Sep 26.
Several mutations in the CFH gene have been described in non-Shiga-toxin-associated haemolytic uraemic syndrome (non-Stx-HUS), a rare syndrome characterized by haemolytic anaemia, thrombocytopenia and acute renal failure. Mutations in genes encoding other complement regulatory proteins, membrane cofactor protein (CD46) and complement factor I (CFI), were also involved in the pathogenesis of the disease. Anyway, mutations in the three genes account for no more than 50% of cases of non-Stx-HUS. Human complement factor H related 5 (CFHR5) is a recently characterised member of the human complement factor H (CFH) family that has been found as a component of immune deposits in human kidney with sclerotic lesions from different causes. CFHR5 possesses cofactor activity and has been proposed to play a role in complement regulation in the glomerulus. We screened CFHR5 gene for variations potentially involved in the aetiology of HUS. Forty-five patients with HUS and 80 controls were analysed. Altogether, 5 genetic variants in CFHR5 were found in overall 9/45 HUS patients and in 4/80 controls. Statistical analysis showed that allelic variants in CFHR5 were prefentially associated with HUS. Based on these data, we conclude that, though not causative, CFHR5 genetic alterations may play a secondary role in the pathogenesis of HUS.
在非志贺毒素相关性溶血尿毒综合征(non-Stx-HUS)中已发现CFH基因的多种突变,该罕见综合征的特征为溶血性贫血、血小板减少和急性肾衰竭。编码其他补体调节蛋白的基因,即膜辅助蛋白(CD46)和补体因子I(CFI)的突变,也参与了该疾病的发病机制。无论如何,这三个基因的突变在非Stx-HUS病例中所占比例不超过50%。人补体因子H相关蛋白5(CFHR5)是人类补体因子H(CFH)家族中最近被鉴定的成员,已被发现是来自不同病因的硬化性病变人肾中免疫沉积物的一个组成部分。CFHR5具有辅助因子活性,并被认为在肾小球补体调节中发挥作用。我们筛查了CFHR5基因中可能与HUS病因相关的变异。对45例HUS患者和80例对照进行了分析。总共在9/45例HUS患者和4/80例对照中发现了CFHR5基因的5种遗传变异。统计分析表明,CFHR5的等位基因变异与HUS优先相关。基于这些数据,我们得出结论,虽然不是致病性的,但CFHR5基因改变可能在HUS的发病机制中起次要作用。